AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC).

Moreover, Downing Street has indicated that the UK will receive "preferential treatment in any further tariffs imposed" as ...

Axtria, an AI-first data analytics innovator focused on transforming life sciences, has announced its highly anticipated ...

In a surprise post this afternoon, new FDA Commissioner Dr Martin Makary announced a completed pilot at the FDA of a ...

The metabolic effects of weight management medicines extend beyond appetite regulation. Still, with more questions about ...

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in ...

According to Politico, Trump will issue an executive order in the next few days to pursue the use of a so-called 'most ...

Shionogi has reached a JPY 151 billion ($1.04 billion) agreement to buy the pharmaceutical subsidiary of Japan Tobacco, Torii ...

In Part 6 of the Life Sciences Industry Report, we’ve collated key thought leadership from 2024 that looks at ways in which ...

Robert F Kennedy Jr has launched a project to trawl federal databases to try to identify why there has been an increase in ...

As NICE begins to incorporate health equity into drug reimbursement decisions, forward-looking pharmaceutical companies have ...

AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...